Is it possible to predict mortality and recurrence of VT afterablation? PAINESD risk score applicability vs new predictors

Autor: AM Martins, P Silverio Antonio, S Couto Pereira, J Brito, B Valente Silva, P Alves Da Silva, AB Garcia, C Simoes De Oliveira, A Nunes Ferreira, G Lima Da Silva, L Carpinteiro, N Cortez-Dias, FJ Pinto, J De Sousa
Rok vydání: 2022
Předmět:
Zdroj: EP Europace. 24
ISSN: 1532-2092
1099-5129
DOI: 10.1093/europace/euac053.089
Popis: Funding Acknowledgements Type of funding sources: None. Introduction Catheter ablation (CA) prevents ventricular tachycardia (VT) recurrences in patients (pts) with structural heart disease (SHD), and might have a favorable outcome, but is associated with severe short-term complications. Identification of pts at high risk of periprocedural acute haemodynamic decompensation has important implications at procedural planning. The PAINESD risk score is a promising tool to predict VT ablation procedure-related mortality. Aim To evaluate the accuracy of the PAINESD risk score to predict short-term mortality after structural VT ablation and to compare it with other conventional clinical predictors. Methods Prospective, observational, single-centre study of consecutive pts with SHD (ischemic or nonischemic), referred for VT-CA. High-density substrate maps were collected, through endocardial, epicardial or combined endo-epicardial approaches according to clinical data and operator preference. The primary endpoint was 30-day mortality or hemodynamic decompensation. Univariate Cox regression analysis was used to identify relevant clinical predictors and to compare them with the PAINESD risk score. Multivariable Cox proportional hazards regression models were used to estimate predictors of 30-day mortality. Results A total of 102 pts with SHD referred for VT ablation were evaluated(mean age: 67±11 years, 94% male, 78.4% in NYHA class I-II; mean LVEF was 34±11%). The baseline PAINESD risk score was 12.39±5.8, 19.6% at low risk, 36.3% at intermediate risk and 27.5% at high risk of adverse events. Overall 30-day mortality was 4.9%. The PAINESD did not predict 30-days mortality or hemodynamic decompensation (p= 0.93). Indeed, a non- significant trend to higher short and long-term mortality was noticed in high-risk score pts – Figure 1. On univariate analysis age>65 years (p=0.019), LVEF Conclusions In our population, LVEF
Databáze: OpenAIRE
Externí odkaz: